Zoledronic acid

Generic Name: Zoledronic acid

Brand Names: Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₀N_₂O_₇P_₂

CAS Number: 118072-93-8

Unique Ingredient Identifier: 70HZ18PH24

Background: Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.

Zoledronic acid was granted FDA approval on 20 August 2001.

Indication: Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.

Associated Conditions: Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease

Associated Therapies: Bone Mineral Density

Clinical Trials

Zoledronic Acid in Acute Spinal Cord Injury

Phase 3

Completed

Conditions: Spinal Cord Injury

Interventions: Drug: normal saline 0.9%
Drug: Zoledronic acid

First Posted Date: 2012-07-17

Last Posted Date: 2023-05-23

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 16

Registration Number: NCT01642901

Locations: 🇺🇸
Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania, United States

Bone Loss Treatment From Adjuvant Zoledronate Efficacy

Not Applicable

Terminated

Conditions: Breast Neoplasms
Bone Loss

Interventions: Drug: Zoledronate

First Posted Date: 2012-06-20

Last Posted Date: 2021-06-22

Lead Sponsor: First Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 200

Registration Number: NCT01623908

Locations: 🇨🇳
Guangzhou First Municipal People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Shenzhen Second Municipal People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

and more 7 locations

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass

Not Applicable

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: Denosumab
Drug: Zoledronic acid

First Posted Date: 2012-04-06

Last Posted Date: 2013-01-17

Lead Sponsor: Aristotle University Of Thessaloniki

Target Recruit Count: 91

Registration Number: NCT01572545

Locations: 🇬🇷
251 Hellenic Air Force Hospital, Athens, Attikis, Greece
🇬🇷
424 General Military Hospital, Thessaloniki, Greece
🇬🇷
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece

FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)

Phase 2

Terminated

Conditions: Osteoporosis

Interventions: Other: FES-Rowing
Drug: Zoledronic acid

First Posted Date: 2011-08-31

Last Posted Date: 2016-04-11

Lead Sponsor: Antonio Lazzari

Target Recruit Count: 70

Registration Number: NCT01426555

Locations: 🇺🇸
Boston VAMC, Boston, Massachusetts, United States
🇺🇸
Spaulding Rehab. Hospital, Charlestown, Massachusetts, United States

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Not Applicable

Terminated

Conditions: Estrogen Receptor-positive Breast Cancer
Invasive Ductal Breast Carcinoma
Stage IB Breast Cancer
Stage IIB Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage IIA Breast Cancer
Stage IA Breast Cancer